Increase of serum creatine phosphokinase in catatonia: An investigation in 32 acute catatonic patients

Psychological Medicine

Volumn 26, Issue 3, 1996, Pages 547-553

  Northoff, G ^a   Wenke, J ^a   Pflug, B ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENPERIDOL; CREATINE KINASE; DOXEPIN; HALOPERIDOL; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CATATONIA; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE CLASSIFICATION; DYSKINESIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; ORAL DRUG ADMINISTRATION; PARKINSONISM;

EID: 0029990410     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0033291700035625     Document Type: Article

References (40)

1. Addonizio, G., Susman, V. L. & Roth, S. D. (1987). Neuroleptic malignant syndrome. review and analysis of 115 cases. Biological Psychiatry 22, 1004-1020.
2. Ainsworth, P (1987). A case of lethal catatonia in a 14 year old girl. British Journal of Psychiatry 150, 110-112.
3. Alexander, G. E., Cratcher, M. D. & DeLong, M. R. (1990). Basal ganglia thalamo cortical circuits. Progress in Brain Research 9, 1-50.
4. American Psychiatric Association (1987). Commitee on nomenclature and statistics, Manual of Mental Disorders, 3rd edn. APA: Washington, DC.
5. Bleuler, E. (1911). Dementia praecox oder die Gruppe der Schizophrenien. Deutricke: Wien.
6. Caroff, S. T. (1980). The neuroleptic malignant syndrome. Journal of Clinical Psychiatry 41, 79-83.
7. Castillo, E , Rubin, R. T. & Hoelsboer-Traechsler, E. (1989). Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. American Journal of Psychiatry 146, 324-328.
8. Cummings, J. L. (1985). Clinical Neuropsychiatry. Stratton: New York
9. Editorial (1986) Catatonia. Lancet ii, 954-956.
10. El-Mallakh, R. S., Egan, M. & Wyatt, R. J. (1992). Creatine kinase and enolase: intracellular enzymes serving as markers of central nervous system damage in neuropsychiatric disorders. Psychiatry 55, 392-402.
11. Endicott, J., Spitzer, R., Flies, J., Schwartz, U. & Fink, U. (1976). The Global Assessment Scale. Archives of General Psychiatry 33, 766-771.
12. Fink, M., Bush, G. & Francis, A. (1993). Catatonia: a treatable disorder occasionally recognized. Directions in Psychiatry 13, 1-7.
13. Fleischhacker, W., Unterweger, B., Kane, J. M. & Hinterhuber, H. (1990) The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatrica Scandinavica 81, 3-5
14. Gelenberg, A J (1976). The catatonic syndrome. Lancet i, 1339-1341.
15. Gelenberg, A. J. (1977). Criteria for the diagnosis of catatonia. American Journal of Psychiatry 134, 462-463.
16. Goode, D J & Meltzer, H J. (1976). Effects of isometric exercise on serum creatine phosphokinase activity Archives of General Psychiatry 33, 1207-1211
17. Guy, W. (1976). Assessment Manual for Psychopharmacology. DHEW 76-338, NIH, Psychopharmacology Research: Rockville, TS.
18. Häfner, H. & Kasper, S. (1982). Akute lebensbedrohliche Katatonie. Nervenarzt 53, 385-394.
19. Hermle, L. & Oepen, G. (1986). Zur Differentialdiagnose der akut lebensbedrohlichen Katatonie und des malignen Neuroleptikasyndromsein kasuistischer Beitrag. Fortschritte der Neurologie und Psychiatrie 54, 189-195.
20. Kahlbaum, K. L. (1874). Die Katatonie. Hirschwald: Berlin.
21. Kraepelin, E. (1905). Lehrbuch der Psychiatrie. Barth: München.
22. Levenson, J. L. (1985). Neuroleptic malignant syndrome. American Journal of Psychiatry 142, 1137-1145.
23. Lohr, J. & Wisniewski, A. (1987). Movement Disorders. Wiley: Chichester
24. McKenna, P., Lund, C., Mortimer, A. & Biggins, C. (1991). Motor, volitional, and behavioural disorders in schizophrenia. British Journal of Psychiatry 158, 323-336.
25. Mann, S. C., Caroff, S. N., Bleier, H. R., Welz, W., Kling, M. & Hayashida, M. (1986). Lethal catatonia. American Journal of Psychiatry 143, 1374-1381.
26. Meltzer, H. Y. (1973). Creatine phosphokinase activity and clinical symptomatology. Archives of General Psychiatry 29, 589-593.
27. Meltzer, H. Y. (1975) Neuromuscular abnormalities in the major mental illnesses. In Biology of the Major Psychoses (ed. D. X. Freedman), pp. 54-72. Blackwell: New York.
28. Meltzer, H. Y. (1976). Serum creatine phosphokinase in schizophrenia. American Journal of Psychiatry 133, 192-197.
29. Menza, M. (1991). Lorazepam and catatonia. Journal of Clinical Psychiatry 52, 186-187.
30. Mortimer, A. M., Lund, C. & McKenna, P. (1990). The positive-negative dichotomy in schizophrenia. British Journal of Psychiatry 157, 41-49.
31. Northoff, G. (1995). Effects of benzodiazepines in catatonia - a pathophysiological model. In Endogenous Psychosis (ed. H. Beckmann and K. J. Neumärker), pp. 145-159. Ullstein Mosby: New York.
32. Overall, J E. & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10, 799-812.
33. Rosalki, S E. (1967). An improved procedure for serum creatine phosphokinase determination. Journal of Laboratory Clinical Medicine 69, 696-705
34. Rosebush, P. & Furlong, M (1991). A consideration of the mechanisms by which lorazepam might treat catatonia Journal of Clinical Psychiatry 52, 187-188.
35. Rosebush, P., Furlong, B. & Mazurek, M. (1990). Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. Journal of Clinical Psychiatry 51, 357-362.
36. Rosebush, P., Furlong, B. & Mazurek, M. (1992). The treatment of catatonia: benzodiazepines or ECT? American Journal of Psychiatry 149, 9-10.
37. Sczesni, B., Schröder, J., Becker, H & Przuntek, H. (1991). Das neuroleptische maligne Syndrom. Wiener Klinische Wochenschrift 103, 1-7.
38. Simpson, G M & Angus, J. W. S. (1970). A rating scale for extrapyramidal side effects Acta Psychiatrica Scandinavica (Suppl.) 212, 11-19
39. Stauder, K H (1934). Die todliche Katatonie. Archiv für Psychiatrie 102, 614-634
40. Taylor, M. (1990). Catatonia: a review of the behavioral neurologic syndrome. Neuropsychiatry, Neuropsychology and Behavioral Neurology 3, 48-72.